Highlights in Chronic Myeloid Leukemia From ASH 2020

Jorge E. Cortes, MD


December 30, 2020

Tyrosine kinase inhibitors (TKIs) are first-line therapy for patients with chronic myeloid leukemia (CML). Successful response to these medications is associated with a life expectancy similar to that of the general population. Many patients have resistance or intolerance to such therapies, however. Dr Jorge Cortes, director of the Georgia Cancer Center at Augusta University, reports on novel medications and critical follow-up studies from the 2020 American Society of Hematology Meeting and Exposition.

Focusing on CML research, Dr Cortes discusses a phase 3 study of a new TKI, asciminib, the first-in-class STAMP inhibitor specifically targeting the Abl myristoyl pocket. The study may lead to this drug's approval in patients who have received two or more TKIs.

Dr Cortes also reports on two new drugs, HQP1351 (olverembatinib) and K0706 (vodobatinib), both reporting very high response rates in treating resistance to first- and second-generation TKIs.

Ponatinib, another novel treatment, shows high response rates and survival outcomes in patients who have had no success with second-generation TKIs.

Finally, the first-ever randomized study comparing the success rate of two frontline TKIs, nilotinib and dasatinib, is presented.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.